Laura Rue
Leuven, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
H-ferritin nanoparticle-mediated antibody delivery across the blood-brain barrier.
Journal: Frontiers in aging neuroscience
Published: March 26, 2026
Targeting EGLN2/PHD1 protects motor neurons and normalizes the astrocytic interferon response.
Journal: Cell reports
Published: March 07, 2024
VHHs as tools for therapeutic protein delivery to the central nervous system.
Journal: Fluids and barriers of the CNS
Published: July 04, 2022
AAV9-mediated gene delivery of MCT1 to oligodendrocytes does not provide a therapeutic benefit in a mouse model of ALS.
Journal: Molecular therapy. Methods & clinical development
Published: August 18, 2020
Environmental enrichment during the chronic phase after experimental stroke promotes functional recovery without synergistic effects of EphA4 targeted therapy.
Journal: Human molecular genetics
Published: September 18, 2019
Lowering EphA4 Does Not Ameliorate Disease in a Mouse Model for Severe Spinal Muscular Atrophy.
Journal: Frontiers in neuroscience
Published: September 10, 2019
EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimer's disease.
Journal: Alzheimer's research & therapy
Published: July 04, 2019
Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.
Journal: Acta neuropathologica communications
Published: May 13, 2019
Heterozygous Deletion of EphrinA5 Does Not Improve Functional Recovery After Experimental Stroke.
Journal: Stroke
Published: March 12, 2019
Elongator subunit 3 (ELP3) modifies ALS through tRNA modification.
Journal: Human molecular genetics
Published: October 24, 2017
Last Updated: 09/26/2026